Galectin-3 Test

Your standard blood work can tell you a lot about your heart, but it has a blind spot: fibrosis. Fibrosis is the slow, silent buildup of scar tissue inside organs, and it is the underlying driver of heart failure, kidney decline, and liver disease. Galectin-3 is one of the few blood tests that directly reflects this scarring process. When your galectin-3 level rises, it means your body's repair machinery has shifted from healing to harmful overdrive, laying down scar tissue that stiffens your heart, clogs your kidneys, or hardens your liver.

The FDA has cleared galectin-3 as a prognostic biomarker in heart failure, and large population studies show it independently predicts heart attacks, strokes, kidney disease, and death. But you do not need a heart failure diagnosis to benefit from knowing your number. In community-dwelling adults without known cardiovascular disease, persistently low galectin-3 levels identified people at very low risk for cardiovascular events over the following decade, performing as well as or better than carotid ultrasound imaging.

What Galectin-3 Is and Where It Comes From

Galectin-3 belongs to a family of proteins called lectins, which bind to sugar molecules on cell surfaces. What makes galectin-3 unusual is its structure: it has a unique tail that lets it link together into clusters, forming lattice-like networks on cell membranes. This clustering ability is what gives it such powerful effects on inflammation and scarring.

The biggest producers of galectin-3 are activated macrophages, the immune cells that rush to sites of tissue injury. When your heart, liver, or kidneys are under stress, macrophages ramp up galectin-3 production, which then stimulates fibroblasts (the cells that build connective tissue) to multiply and deposit collagen. Fat cells are another major source. In people who carry excess weight, enlarged fat cells pour galectin-3 into the bloodstream, which helps explain the strong link between obesity and organ scarring.

Heart Disease and Heart Failure Risk

The strongest evidence for galectin-3 comes from cardiovascular disease. In the ARIC study, which tracked over 9,200 adults without cardiovascular disease for roughly 18 years, each standard-deviation increase in log-transformed galectin-3 was linked to a 44% higher risk of developing heart failure, a 30% higher risk of coronary heart disease, a 42% higher risk of stroke, and a 56% higher risk of death from any cause, after adjusting for traditional risk factors.

These findings held up in the Framingham Offspring Study, where rising galectin-3 over a decade predicted new heart failure with a 39% higher risk per standard-deviation increase in log-transformed galectin-3, and new cardiovascular disease with a 29% higher risk per standard-deviation increase. People whose levels stayed elevated at both time points had the worst outcomes.

After a heart attack, galectin-3 is an especially strong predictor of survival. In a population-based study of 1,342 heart attack patients followed for about 5 years, those in the highest third of galectin-3 levels had a 5-year mortality rate of 51.9%, compared to just 10.2% in the lowest third. Each 10-unit increase in galectin-3 corresponded to a 30% increase in the risk of death.

Galectin-3 appears especially useful for a type of heart failure called HFpEF (heart failure with preserved ejection fraction), where the heart's pumping percentage looks normal but the muscle has become stiff and cannot relax properly. Standard tests often miss HFpEF in its early stages. In one study, galectin-3 was the most accurate discriminator of 5-year risk in HFpEF patients, outperforming BNP (a standard heart failure marker).

Kidney Disease

Galectin-3 does not just reflect cardiac scarring. It also tracks fibrosis in the kidneys, and elevated levels precede the development of chronic kidney disease. In the ARIC study, people in the highest quarter of galectin-3 levels were about twice as likely to develop chronic kidney disease compared to those in the lowest quarter (after adjusting for existing kidney function, protein in the urine, and other cardiac biomarkers). The Framingham study confirmed this, finding a 47% higher odds of developing kidney disease per standard-deviation increase.

In people with type 2 diabetes, galectin-3 independently predicted kidney deterioration, defined as a doubling of serum creatinine or needing dialysis, even after accounting for baseline kidney function and urine protein levels. This makes galectin-3 one of the few biomarkers that can flag kidney trouble before it shows up on standard tests like creatinine or eGFR.

Liver Disease

The liver is another organ where galectin-3 tracks fibrotic damage. Levels are elevated in people with fatty liver disease that has progressed to active liver inflammation (a condition called nonalcoholic steatohepatitis, or NASH), cirrhosis, and liver cancer. Galectin-3 activates the specialized cells in the liver (called hepatic stellate cells) that drive scar tissue formation when they are switched on by chronic injury.

Cancer Associations

Galectin-3 plays a role in how cancers grow and spread. It helps tumor cells stick to blood vessel walls, evade the immune system, and establish new blood supply. A meta-analysis of 36 studies found that elevated galectin-3 was associated with roughly 79% worse overall survival and 57% worse disease-free survival across multiple cancer types. The association was strongest in colorectal cancer, where elevated galectin-3 was linked to about 3 times the risk of death, and in ovarian cancer and non-small cell lung cancer, where it was linked to roughly double the risk.

The Protective Value of Low Levels

One of the most practical findings about galectin-3 is what a low result tells you. In the BioImage study of nearly 6,000 older adults, those with galectin-3 below the 25th percentile (roughly below 9 to 11 ng/mL depending on the population) had a very low probability of cardiovascular events over the following years. This negative predictive value performed as well as or better than carotid ultrasound for ruling out cardiovascular risk. If your galectin-3 is low, that is strong reassurance that your organs are not accumulating significant scar tissue.

Reference Ranges

Kidney function is the single biggest confounder of galectin-3 interpretation. Levels climb as kidney filtration declines, so you should always interpret your galectin-3 result alongside your eGFR. A galectin-3 of 18 ng/mL means something very different in someone with perfect kidney function versus someone whose kidneys are filtering at half capacity.

These tiers are drawn from published research, including large population studies and the 97.5th percentile of healthy adults. Your lab may use different assays and cutpoints. Compare your results within the same lab over time for the most meaningful trend. Women tend to run slightly higher than men (median around 11.0 vs. 10.7 ng/mL in the general population), and levels increase modestly with age, though a single set of adult reference ranges is generally considered sufficient.

Tracking Your Trend

Galectin-3 is one of the most stable cardiac biomarkers available, with within-person variation of only 4.5 to 7.1% over weeks to months. That is far lower than BNP, which can swing 22 to 35% from one draw to the next. This stability means that when your galectin-3 number moves, the change is more likely to reflect a real shift in your biology rather than random lab noise.

That said, a single reading is a snapshot, not the full picture. Studies consistently show that tracking galectin-3 over time adds information beyond any one-time measurement. In the Framingham study, people whose galectin-3 rose over 10 years had significantly higher rates of heart failure, cardiovascular disease, and death compared to those whose levels stayed stable. The time your galectin-3 spends below 20 ng/mL appears to predict whether your heart can recover its pumping function after damage.

When Results Can Be Misleading

Because galectin-3 must be about 61 to 78% higher (or about half as low) to confirm a true biological change from one draw to the next, modest fluctuations between readings are usually noise. Keep this reference change value in mind before reacting to a small shift.

• Kidney function: This is the most common source of false elevation. Mean galectin-3 rises from about 12.8 ng/mL in people with normal kidney filtration to 23.1 ng/mL in those with significantly reduced filtration. If your eGFR is below 60 mL/min, your galectin-3 will likely be higher regardless of cardiac fibrosis status.
• Acute infection or illness: Infections, sepsis, and severe COVID-19 all spike galectin-3 substantially. Wait at least 2 to 4 weeks after recovering from any significant illness before testing.
• Vigorous exercise: A marathon or similar intense endurance event can push galectin-3 from around 12.8 to 19.9 ng/mL immediately afterward, though levels return to baseline within a few hours. This spike comes from skeletal muscle, not the heart. Avoid testing within 4 hours of intense exercise.
• Metformin use: Metformin is associated with lower galectin-3 levels in people with type 2 diabetes and obesity. If you are taking metformin, your result may underestimate your true fibrotic activity. This does not mean you should stop metformin; just factor it into interpretation.